TulmiSTAR-02: tulmimetostat with Daro or Abi for mHSPC

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in combination with darolutamide versus darolutamide alone in patients with metastatic hormone-sensitive prostate cancer, CDZR123C12101
Principal Investigator
Headshot of Jeffrey William Shevach
Assistant Professor of Medicine
Protocol Number
IRB: PRO00119024
NCT: NCT07190300
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL